In a groundbreaking move, Axogen, Inc. a leading player in the field of innovative surgical solutions for peripheral nerve injuries, has recently announced the full launch of their newest product, Avive+ Soft Tissue Matrix. This resorbable, multi-layer amniotic membrane allograft is designed to act as a soft tissue barrier, offering temporary protection and tissue separation during the critical phase of peripheral nerve healing. This exciting development aligns with the U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, as well as U.S. State regulations as a 361 human tissue product.
Factual Overview
Axogen, Inc. has made significant strides in developing and marketing groundbreaking surgical solutions for peripheral nerve injuries, cementing their position as a global industry leader. With the full launch of their latest product, Avive+ Soft Tissue Matrix, the company has introduced an advanced technology that promises to revolutionize the field of peripheral nerve healing.
Avive+ is an amniotic membrane allograft that provides vital support during the crucial phase of peripheral nerve recovery. As a resorbable product, it offers temporary tissue protection and separation, allowing for optimal healing. The meticulous processing and distribution of Avive+ align closely with stringent FDA requirements for Human Cellular and Tissue-based Products (HCT/P), affirming Axogen’s commitment to product safety and regulatory compliance.
Assessing the Impact on Axogen, Inc.:
The launch of Avive+ Soft Tissue Matrix is a significant milestone for Axogen, Inc. positioning the company at the forefront of innovation in peripheral nerve injury solutions. By expanding its product portfolio, Axogen is set to reach a wider customer base and capture greater market share.
With Avive+, Axogen addresses a critical need in peripheral nerve healing by offering a resorbable soft tissue barrier that aids the recovery process. This development showcases the company’s commitment to meeting healthcare professionals’ requirements and improving patient outcomes.
Moreover, by adhering to strict FDA guidelines for HCT/P products, Axogen reinforces its reputation as a reliable and responsible provider of surgical solutions, further instilling trust among surgeons and hospitals.
Comments